Kaneka Eurogentec vs Pharmaron: CDMO Comparison
How does Kaneka Eurogentec compare to Pharmaron for Plasmid DNA manufacturing?
Side-by-side comparison of Kaneka Eurogentec and Pharmaron on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Pharmaron has more FDA inspections on record (5 vs 1) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Kaneka Eurogentec holds 4 active EMA GMP certificates; Pharmaron does not appear in EudraGMDP.
- Pharmaron maintains 1 MHRA / UK GMP certificate; Kaneka Eurogentec does not.
On a 13-modality CDMO landscape, both Kaneka Eurogentec and Pharmaron qualify as Plasmid DNA manufacturers; Pharmaron carries the higher composite Signal Score for Plasmid DNA programs in this comparison.
What to evaluate for Plasmid DNA programs
Both Kaneka Eurogentec and Pharmaron qualify as Plasmid DNA CDMOs. When choosing between them for Plasmid DNA programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
GMP grade & purity
Confirm GMP (vs research/HQ) grade, supercoiled percentage, and residual host-cell DNA/RNA and endotoxin specs — these gate downstream vector and mRNA quality.
Fermentation scale & yield
Match fermentation scale and yield to your vector or mRNA demand. Ask about high-yield strains and whether scale-up is validated.
Lead time
Plasmid is a common critical-path bottleneck. Evaluate realistic queue and turnaround against your program timeline.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: Kaneka Eurogentec vs Pharmaron
How does Kaneka Eurogentec compare to Pharmaron for Plasmid DNA manufacturing?
On CDMO Signal's composite Signal Score, Kaneka Eurogentec is 80/100 and Pharmaron is 87/100; Kaneka Eurogentec has 1 FDA inspection on record vs 5 for Pharmaron; European coverage is 4 active EMA+MHRA certificates for Kaneka Eurogentec vs 1 for Pharmaron. Both are tracked in the CDMO Signal directory as Plasmid DNA CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Kaneka Eurogentec or Pharmaron?
Both Kaneka Eurogentec and Pharmaron maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Kaneka Eurogentec has 1 FDA inspection on record; Pharmaron has 5.
How do Kaneka Eurogentec and Pharmaron compare on European GMP coverage?
Kaneka Eurogentec holds 4 active EMA GMP certificates and 0 MHRA / UK certificates. Pharmaron holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for Plasmid DNA manufacturing — Kaneka Eurogentec or Pharmaron?
Both Kaneka Eurogentec and Pharmaron are tagged as Plasmid DNA CDMOs in our directory, so both are credible options for Plasmid DNA programs. The most important differentiator for Plasmid DNA selection is typically gmp grade & purity: Confirm GMP (vs research/HQ) grade, supercoiled percentage, and residual host-cell DNA/RNA and endotoxin specs — these gate downstream vector and mRNA quality. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Kaneka Eurogentec carries a Signal Score of 80/100 and Pharmaron carries 87/100 — a small lead for Pharmaron. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →